More Stories

Informist, Tuesday, May 12, 2026

 

Please click here to read all liners published on this story

--Dr Reddy's: See peptides, biosimilars, consumer health as growth drivers 
--CONTEXT: Dr Reddy's mgmt's comments at post-earnings virtual press meet 
--Dr Reddy's: Will launch Semaglutide in Canada in coming days 
--Dr Reddy's: Will launch Semaglutide tablet in India soon 
--Dr Reddy's: Logistical impact from West Asia war on co not material 
--Dr Reddy's: Capex planned for FY27 INR 20 billion 
--Dr Reddy's: Some, not material, shipping freight increase due to W Asia war 
--Dr Reddy's: Already using alternative shipping routes due to West Asia war 
--Dr Reddy's:Plan to launch Semaglutide in multiple emerging mkts next 12 mos 
--Dr Reddy's: Looking for acquisition targets all the time 
--Dr Reddy's: Constantly evaluating India pdt portfolio for brand divestments 
--Dr Reddy's: R&D spend will be in range of 7-8% of sales for FY27 
 

 

By Gunjan Rajput and Rajesh Gajra 

 

NEW DELHI – Dr. Reddy's Laboratories plans to incur capital expenditure of INR 20 billion in the financial year 2025-27 (Apr-Mar), while research and development spending is expected to remain in the range of 7-8% of sales, the company's management said at a post-earnings virtual press meeting on Tuesday. 

 

The company plans to introduce Semaglutide tablets in India soon, and the price range will be competitive. In March, the company launched its generic semaglutide injection in India under the brand name Obeda, with cost to patient at INR 4,200 per month for a minimum of four weekly doses. "First from a point of India.....when you look into the volumes, especially telzapetide, continue to do well. It is a small drop when it comes to the oral semaglutide, but when it comes to the generic semaglutide, they have really taken off, and there is significant growth in the market," the management said.

Also, the company had in April got approval from Health Canada for its generic version of injectable semaglutide, and now will launch Semaglutide in Canada in the coming few days. The company also said it aims to launch Semaglutide in multiple emerging markets over the next 12 months. The drugmaker said peptides, biosimilars and consumer healthcare will be key growth drivers going ahead.

 

On the fall in volume and price of drug Lenalidomide in which US volume limits were removed at the end of January, resulting in the company's March quarter revenue from operations falling sharply by 12% on year to INR 75.46 billion, the management said the company already did not sell the drug from up to a month earlier. On the geopolitical front, the company said the ongoing West Asia war has not had a material logistical impact on operations so far. While freight costs have seen some increase due to the conflict, the impact is not material, it said, adding that the company is already using alternative shipping routes. "We have found alternative shipping routes... (to) get the products to all the markets that we are operating. At this point of time there is no immediate concern of non-availability of our products in any of the markets," the management added. 

 

The pharma company also said it is continuously evaluating acquisition opportunities. "We are looking at targets all the time" for adding assets in genetics, bilogics, consumer health, and innovation, to our pool, a top official said.

 

Dr Reddy's is also reviewing its India product portfolio for potential brand divestment, as per the official. "We are constantly looking into our portfolio and seeing if there are some brands which are largely tail-end, which don't fit our portfolio, and it is better that we deprioritise them," he said.

 

The company said its business is expected to grow at a double-digit pace even without semaglutide launches, supported by over 100 product launches planned over the next 12 months, including 27 launches in the US market. "We are looking for a very healthy growth in the next 12 months as well as in the coming years," the management said. 

 

Dr. Reddy's Laboratories Tuesday reported a consolidated net profit of INR 2.21 billion for the March quarter on revenues of INR 75.46 billion. Shares of the company ended at INR 1,270 on the National Stock Exchange, down 0.8%.  End

 

Edited by Avishek Dutta

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (11) 4220-1000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.